Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44

Oncology Letters

Volumn 3, Issue 6, 2012, Pages 1186-1190

  Tajima, Hidehiro ^a   Ohta, Tetsuo ^a   Kitagawa, Hirohisa ^a   Okamoto, Koichi ^a   Sakai, Seisho ^a   Kinoshita, Jun ^a   Makino, Isamu ^a   Furukawa, Hiroyuki ^a   Hayashi, Hironori ^a   Nakamura, Keishi ^a   Oyama, Katsunobu ^a   Inokuchi, Masafumi ^a   Nakagawara, Hisatoshi ^a   Fujita, Hideto ^a   Takamura, Hiroyuki ^a   Ninomiya, Itasu ^a   Fushida, Sachio ^a   Tani, Takashi ^a   Fujimura, Takashi ^a   Kitamura, Seiko ^b   Ikeda, Hiroko ^b   Tsuneyama, Koichi ^c   more..

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c TOYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Cancer stem cells; Epithelial to mesenchymal transition; Gemcitabine; Neoadjuvant chemotherapy; Pancreatic cancer

Indexed keywords

GEMCITABINE; HERMES ANTIGEN; M30 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER STEM CELL; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; PANCREAS ADENOCARCINOMA; PERINEURIUM; PROTEIN EXPRESSION; RETROPERITONEUM; SEROSA; TUMOR VOLUME;

EID: 84859456513     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.657     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 58: 71-96, 2008.
3. Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinico-pathologic analysis of 5-year survivors. Ann Surg 223: 273-279, 1996.
4. Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic cancer registry in Japan: 20 years of experience. Pancreas 28: 219-230, 2004.
5. Kayahara M, Nagakawa T, Ueno K, et al: An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72: 2118-2123, 1993.
6. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
7. Ottle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007.
8. Golcher H, Brunner T, Grabenbauer G, et al: Preoperative chemo-radiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. EJSO 34: 756-764, 2008.
9. Goses MJ, Dressen RC, Rutten HJ, et al: Prepoerative radio-chemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumors. Ann Oncol 19: 2026-2032, 2008.
10. Yang AD, Fan F, Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
11. Tsukamoto H, Shibata K, Kajiyama H, et al: Irradiation-induced epithelial-mesencymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecol Oncol 107: 500-504, 2007.
12. Tajima H, Ohta T, Shoji Y, et al: Expression of epithelial-mesenchymal transition markers in locally recurrent hepatocellular carcinoma after radiofrequency ablation. Exp Therap Med 1: 347-350, 2010.
13. Shah AN, Summy JM, Zhang J, Park SI, Darikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007.
14. Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.
15. Hay ED and Zuk A: Transformations between epithelium and mesenchyme: normal, pathological and experimentally induced. Am J Kidney Dis 26: 678-690, 1995.
16. Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2: 442-454, 2002.
17. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
18. Kikuta K, Masamune A, Watanabe T, et al: Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 403: 380-384, 2010.
19. Evans DB, Rich TA, Byrd DR, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127: 1335-1339, 1992.
20. Dive C, Smith RA, Garner E, et al: Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer 102: 577-582, 2010.
21. Du Z, Qin R, Wei C, et al: Pancreatic cancer cells resistant to chemoradiotherapy rich in 'stem-cell-like' tumor cells. Dig Dis Sci 10: 741-750, 2010.
22. Hong SP, Wen J, Bang S, Park S and Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125: 2323-2331, 2009.
23. Müerköster SS, Werbing V, Koch D, et al: Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma - epigenetic downregulation of caspase. Int J Cancer 123: 1751-1760, 2008.
24. Yin T, Wang C, Liu T, Zhao G, Zha Y and Yang M: Expression of Snail in pancreatic cancer promotes metastasis and chemoresistsance. J Surg Res 141: 196-203, 2007.
25. Cauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cicplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19: 1592-1599, 2008.
26. Van Laethem JL, Hammel P, Mornex F, et al: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012 /FFCD-9203/GERCOR phase II study. J Clin Oncol 28: 4450-4456, 2010.